| Drug General Information |
| Drug ID |
D0DJ1B
|
| Former ID |
DIB008644
|
| Drug Name |
Naproxen
|
| Synonyms |
Naprelan; Naproxen Sodium; Naprelan; Aleve; Anaprox; Anaprox Ds
|
| Drug Type |
Small molecular drug
|
| Indication |
Osteoarthritis; Rheumatoid arthritis [ICD9: 714, 715; ICD10:M05-M06, M15-M19, M47]
|
Approved |
[1]
|
|---|
|
Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]
|
Phase 2 |
[2],
[3]
|
| Company |
Iroko pharmaceuticals; PLx Pharma; CeNeS Pharmaceuticals plc
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H14O3
|
| InChIKey |
CMWTZPSULFXXJA-VIFPVBQESA-N
|
| CAS Number |
CAS 22204-53-1
|
| PubChem Compound ID |
|
| PubChem Substance ID |
4682, 597410, 3248704, 7847186, 7980083, 8149438, 10252902, 10321400, 11112669, 11335417, 11360656, 11363871, 11366433, 11368995, 11371667, 11373736, 11377157, 11461628, 11466819, 11467939, 11484702, 11486597, 11488859, 11490330, 11491884, 11494791, 15172373, 15172374, 22391409, 24857178, 24870224, 24883816, 24897861, 25649496, 26527900, 26611833, 26679674, 26755231, 46232210, 46487915, 46505508, 47291026, 47588882, 47810639, 48334369, 48334370, 48426145, 49833549, 50025704, 50103854
|
| Target and Pathway |
| Target(s) |
Prostaglandin G/H synthase 2 |
Target Info |
Inhibitor |
[4]
|
|---|
| Prostaglandin G/H synthase 1 |
Target Info |
Inhibitor |
[4]
|
|
BioCyc Pathway
|
Aspirin-triggered lipoxin biosynthesis
|
|
Aspirin triggered resolvin D biosynthesis
|
|
C20 prostanoid biosynthesis
|
|
Aspirin triggered resolvin E biosynthesisPWY66-374:C20 prostanoid biosynthesis
|
|
KEGG Pathway
|
Arachidonic acid metabolism
|
|
Metabolic pathways
|
|
NF-kappa B signaling pathway
|
|
VEGF signaling pathway
|
|
TNF signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Serotonergic synapse
|
|
Ovarian steroidogenesis
|
|
Oxytocin signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Leishmaniasis
|
|
Pathways in cancer
|
|
Chemical carcinogenesis
|
|
MicroRNAs in cancer
|
|
Small cell lung cancerhsa00590:Arachidonic acid metabolism
|
|
Platelet activation
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
TSH Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
IL5 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Endothelin signaling pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Toll receptor signaling pathway
|
|
CCKR signaling map STP00031:Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Pathway Interaction Database
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
S1P1 pathway
|
|
C-MYB transcription factor network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
Calcium signaling in the CD4+ TCR pathway
|
|
PathWhiz Pathway
|
Arachidonic Acid MetabolismPW000044:Arachidonic Acid Metabolism
|
|
WikiPathways
|
Prostaglandin Synthesis and Regulation
|
|
Arachidonic acid metabolism
|
|
Aryl Hydrocarbon Receptor
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Eicosanoid Synthesis
|
|
Selenium Micronutrient NetworkWP98:Prostaglandin Synthesis and Regulation
|
|
Phase 1 - Functionalization of compounds
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5230). |
|---|
| REF 3 | ClinicalTrials.gov (NCT01139190) Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults. U.S. National Institutes of Health. |
|---|
| REF 4 | Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20. |
|---|
